Is Arcturus Therapeutics Stock a Good Investment?
Arcturus Therapeutics Investment Advice | ARCT |
- Examine Arcturus Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Arcturus Therapeutics' leadership team and their track record. Good management can help Arcturus Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Arcturus Therapeutics' business and its evolving consumer preferences.
- Compare Arcturus Therapeutics' performance and market position to its competitors. Analyze how Arcturus Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Arcturus Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Arcturus Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Arcturus Therapeutics Holdings stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Arcturus Therapeutics Holdings is a good investment.
Sell | Buy |
Hold
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Arcturus Therapeutics Stock
Researching Arcturus Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 90.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.75. Some equities with similar Price to Book (P/B) outperform the market in the long run. Arcturus Therapeutics has Price/Earnings (P/E) ratio of 119.5. The entity recorded a loss per share of 2.33. The firm last dividend was issued on the 16th of November 2017. Arcturus Therapeutics had 1:7 split on the 16th of November 2017.
To determine if Arcturus Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Arcturus Therapeutics' research are outlined below:
| Arcturus Therapeutics generated a negative expected return over the last 90 days | |
| Arcturus Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 157.75 M. Net Loss for the year was (29.73 M) with profit before overhead, payroll, taxes, and interest of 62.95 M. | |
| Arcturus Therapeutics Holdings currently holds about 283.49 M in cash with (18.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.67. | |
| Arcturus Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 90.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Acquisition by Marantz Jing L. of 11869 shares of Arcturus Therapeutics at 34.92 subject to Rule 16b-3 |
Arcturus Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Arcturus Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Arcturus Therapeutics Holdings. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Arcturus Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Arcturus Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Arcturus Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2019-05-13 | 2019-03-31 | -0.58 | -0.65 | -0.07 | 12 | ||
2018-11-07 | 2018-09-30 | -0.56 | -0.42 | 0.14 | 25 | ||
2024-05-08 | 2024-03-31 | -1.19 | -1.0 | 0.19 | 15 | ||
2019-11-07 | 2019-09-30 | -0.36 | -0.56 | -0.2 | 55 | ||
2020-03-11 | 2019-12-31 | -0.53 | -0.76 | -0.23 | 43 | ||
2022-02-28 | 2021-12-31 | -1.72 | -1.47 | 0.25 | 14 | ||
2016-05-16 | 2016-03-31 | -1.51 | -1.26 | 0.25 | 16 | ||
2016-02-17 | 2015-12-31 | -1.68 | -1.4 | 0.28 | 16 |
Know Arcturus Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Arcturus Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Arcturus Therapeutics Holdings backward and forwards among themselves. Arcturus Therapeutics' institutional investor refers to the entity that pools money to purchase Arcturus Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 551.8 K | Portolan Capital Management, Llc | 2024-06-30 | 484.9 K | Goldman Sachs Group Inc | 2024-06-30 | 445.5 K | Fmr Inc | 2024-09-30 | 443 K | Schonfeld Strategic Advisors Llc | 2024-09-30 | 369.6 K | Wellington Management Company Llp | 2024-06-30 | 360.7 K | Jupiter Asset Management Limited | 2024-09-30 | 352 K | Jpmorgan Chase & Co | 2024-06-30 | 272 K | Northern Trust Corp | 2024-09-30 | 242.8 K | Federated Hermes Inc | 2024-09-30 | 4.7 M | Blackrock Inc | 2024-06-30 | 2.6 M |
Arcturus Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 474.3 M.Market Cap |
|
Arcturus Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.07) | (0.07) | |
| Return On Capital Employed | (0.23) | (0.24) | |
| Return On Assets | (0.07) | (0.07) | |
| Return On Equity | (0.11) | (0.11) |
Determining Arcturus Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Arcturus Therapeutics is a good buy. For example, gross profit margin measures Arcturus Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Arcturus Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Arcturus Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Arcturus Therapeutics Holdings. Check Arcturus Therapeutics' Beneish M Score to see the likelihood of Arcturus Therapeutics' management manipulating its earnings.
Evaluate Arcturus Therapeutics' management efficiency
Arcturus Therapeutics has return on total asset (ROA) of (0.1215) % which means that it has lost $0.1215 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2312) %, meaning that it created substantial loss on money invested by shareholders. Arcturus Therapeutics' management efficiency ratios could be used to measure how well Arcturus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.07 in 2024. Return On Capital Employed is likely to drop to -0.24 in 2024. At this time, Arcturus Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 450.9 M in 2024, whereas Non Current Liabilities Total is likely to drop slightly above 38.6 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 10.46 | 11.99 | |
| Tangible Book Value Per Share | 10.46 | 12.73 | |
| Enterprise Value Over EBITDA | (23.91) | (25.10) | |
| Price Book Value Ratio | 3.01 | 3.17 | |
| Enterprise Value Multiple | (23.91) | (25.10) | |
| Price Fair Value | 3.01 | 3.17 | |
| Enterprise Value | 91.6 M | 86.5 M |
Arcturus Therapeutics showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Beta 2.64 |
Basic technical analysis of Arcturus Stock
As of the 28th of November, Arcturus Therapeutics shows the mean deviation of 3.15, and Risk Adjusted Performance of (0.02). Arcturus Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Arcturus Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Arcturus Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Arcturus Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Arcturus Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Arcturus Therapeutics' Outstanding Corporate Bonds
Arcturus Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Arcturus Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Arcturus bonds can be classified according to their maturity, which is the date when Arcturus Therapeutics Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US039653AA89 Corp BondUS039653AA89 | View | |
| Ardagh Holdings USA Corp BondUS03969AAP57 | View | |
| Ardagh Holdings USA Corp BondUS03969AAN00 | View | |
| Ardagh Packaging Finance Corp BondUS03969AAR14 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| US03969YAA64 Corp BondUS03969YAA64 | View | |
| US03969YAB48 Corp BondUS03969YAB48 | View | |
| AMPBEV 6 15 JUN 27 Corp BondUS03969YAC21 | View |
Understand Arcturus Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Arcturus Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.12) | |||
| Mean Deviation | 3.15 | |||
| Coefficient Of Variation | (2,539) | |||
| Standard Deviation | 4.13 | |||
| Variance | 17.03 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.33) | |||
| Total Risk Alpha | (0.79) | |||
| Treynor Ratio | (0.13) | |||
| Maximum Drawdown | 21.47 | |||
| Value At Risk | (5.87) | |||
| Potential Upside | 5.57 | |||
| Skewness | (0.27) | |||
| Kurtosis | 1.12 |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.12) | |||
| Mean Deviation | 3.15 | |||
| Coefficient Of Variation | (2,539) | |||
| Standard Deviation | 4.13 | |||
| Variance | 17.03 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.33) | |||
| Total Risk Alpha | (0.79) | |||
| Treynor Ratio | (0.13) | |||
| Maximum Drawdown | 21.47 | |||
| Value At Risk | (5.87) | |||
| Potential Upside | 5.57 | |||
| Skewness | (0.27) | |||
| Kurtosis | 1.12 |
Consider Arcturus Therapeutics' intraday indicators
Arcturus Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Arcturus Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Arcturus Therapeutics Corporate Filings
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 16th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 17th of July 2024 Other Reports | ViewVerify |
Arcturus Stock media impact
Far too much social signal, news, headlines, and media speculation about Arcturus Therapeutics that are available to investors today. That information is available publicly through Arcturus media outlets and privately through word of mouth or via Arcturus internal channels. However, regardless of the origin, that massive amount of Arcturus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Arcturus Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Arcturus Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Arcturus Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Arcturus Therapeutics alpha.
Arcturus Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Arcturus Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Arcturus Therapeutics Corporate Management
| Roberta Duncan | Chief Officer | Profile | |
| Lance Kurata | Chief Officer | Profile | |
| FCPh MD | Chief Officer | Profile | |
| Kyle Gutstadt | Analyst PR | Profile | |
| Joseph Roberts | Controller | Profile | |
| Andrew MBA | CFO Director | Profile | |
| Joseph MSc | President, Founder | Profile |
Already Invested in Arcturus Therapeutics Holdings?
The danger of trading Arcturus Therapeutics Holdings is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Arcturus Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Arcturus Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Arcturus Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Arcturus Stock Analysis
When running Arcturus Therapeutics' price analysis, check to measure Arcturus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcturus Therapeutics is operating at the current time. Most of Arcturus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arcturus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcturus Therapeutics' price. Additionally, you may evaluate how the addition of Arcturus Therapeutics to your portfolios can decrease your overall portfolio volatility.